All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The latest on SMM
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Mutiple Myeloma Hub spoke to Timothy M. Schmidt, University of Wisconsin-Madison, Madison, US. We asked about updates to the NCCN guidelines for the diagnosis and treatment of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM).
For MGUS, Schmidt discusses the addition of the new term, 'monoclonal gammopathy of neurological significance', for patients with IgM polyneuropathy. For SMM, Schmidt highlights the use of the 20:2:20 risk stratification criteria to identify high-risk SMM and discusses treatment options for this group of patients.
The latest on SMM
Subscribe to get the best content related to multiple myeloma delivered to your inbox